-
NMPA Announcement on Matters Related to the Implementation of the 2025 Edition of the Pharmacopoeia of the People's Republic of China (No. 32, 2025)
2025-06-11
The 2025 Edition of the Pharmacopoeia of the People's Republic of China (hereinafter referred to as the Chinese Pharmacopoeia) has been issued by Announcement No. 29, 2025 of the National Medical Products Administration and the National Health Commission and shall come into force as of October 01, 2025.
-
Transcatheter Mitral Valve Clip System Approved for Marketing
2025-06-11
Recently, the innovative product Transcatheter Mitral Valve Clip System of Hangzhou Dawneo Medical Technology Co., Ltd. is approved by China NMPA.
-
Aortic Covered Stent System Approved for Marketing
2025-06-11
Recently, the innovative product "Aortic Covered Stent System" of Lifetech Scientific (Shenzhen) Co., Ltd. is approved by China NMPA.
-
Interpretation of the NMPA Announcement on Further Adjustment and Optimization of Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China
2025-06-11
The NMPA Announcement on Further Adjustment and Optimization of Matters Concerning the Production of Imported Medical Devices in Domestic Enterprises in China (No. 30, 2025) was issued on March 18, 2025.
-
NMPA Announcement on Issuing the Pharmaceutical Excipients Annex and Pharmaceutical Packaging Materials Annex of the Good Manufacturing Practice for Drugs (2010 Revision) (No.1, 2025)
2025-06-11
To implement relevant regulations such as the Drug Administration Law of the People's Republic of China, the Regulations for the Implementation of the Drug Administration Law of the People's Republic of China, the Provisions for Drug Registration, and the Provisions for Drug Manufacturing Supervision and Administration, and to supervise and guide the standardized production of pharmaceutical excipients and pharmaceutical packaging materials manufacturers, the National Medical Products Administration has organized the formulation of the Pharmaceutical Excipients Annex and Pharmaceutical Packaging Materials Annex.
-
Zolbetuximab for Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Zolbetuximab for Injection (trade name: 威络益/VYLOY) of Astellas Pharma Europe B.V. is approved for marketing by China NMPA.
